These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 32818555)
21. Effect of ruxolitinib therapy on the quality-of-life of Japanese patients with myelofibrosis. Oritani K; Ohishi K; Okamoto S; Kirito K; Komatsu N; Tauchi T; Handa H; Saito S; Takenaka K; Shimoda K; Okada H; Amagasaki T; Wakase S; Shimozuma K; Akashi K Curr Med Res Opin; 2018 Mar; 34(3):531-537. PubMed ID: 29224367 [TBL] [Abstract][Full Text] [Related]
22. Recurrent Subcutaneous Sweet's Disease in a Myelofibrosis Patient Treated with Ruxolitinib before Allogeneic Stem Cell Transplantation. Sakoda T; Kanamitsu Y; Mori Y; Sasaki K; Yonemitsu E; Nagae K; Yoshimoto G; Kamezaki K; Kato K; Takenaka K; Miyamoto T; Furue M; Iwasaki H; Akashi K Intern Med; 2017 Sep; 56(18):2481-2485. PubMed ID: 28824063 [TBL] [Abstract][Full Text] [Related]
23. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib. Bryan JC; Verstovsek S Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614 [TBL] [Abstract][Full Text] [Related]
30. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. Harrison C; Kiladjian JJ; Al-Ali HK; Gisslinger H; Waltzman R; Stalbovskaya V; McQuitty M; Hunter DS; Levy R; Knoops L; Cervantes F; Vannucchi AM; Barbui T; Barosi G N Engl J Med; 2012 Mar; 366(9):787-98. PubMed ID: 22375970 [TBL] [Abstract][Full Text] [Related]
31. Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation. Kuykendall AT; Shah S; Talati C; Al Ali N; Sweet K; Padron E; Sallman DA; Lancet JE; List AF; Zuckerman KS; Komrokji RS Ann Hematol; 2018 Mar; 97(3):435-441. PubMed ID: 29189896 [TBL] [Abstract][Full Text] [Related]
32. Ruxolitinib for myelofibrosis--an update of its clinical effects. Kantarjian HM; Silver RT; Komrokji RS; Mesa RA; Tacke R; Harrison CN Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):638-45. PubMed ID: 24238036 [TBL] [Abstract][Full Text] [Related]
33. Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval. Verstovsek S; Parasuraman S; Yu J; Shah A; Kumar S; Xi A; Harrison C Ann Hematol; 2022 Jan; 101(1):131-137. PubMed ID: 34625831 [TBL] [Abstract][Full Text] [Related]
34. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Harrison CN; Vannucchi AM; Platzbecker U; Cervantes F; Gupta V; Lavie D; Passamonti F; Winton EF; Dong H; Kawashima J; Maltzman JD; Kiladjian JJ; Verstovsek S Lancet Haematol; 2018 Feb; 5(2):e73-e81. PubMed ID: 29275119 [TBL] [Abstract][Full Text] [Related]
35. Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial. Mead AJ; Milojkovic D; Knapper S; Garg M; Chacko J; Farquharson M; Yin J; Ali S; Clark RE; Andrews C; Dawson MK; Harrison C Br J Haematol; 2015 Jul; 170(1):29-39. PubMed ID: 25824940 [TBL] [Abstract][Full Text] [Related]
36. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. Verstovsek S; Mesa RA; Gotlib J; Levy RS; Gupta V; DiPersio JF; Catalano JV; Deininger M; Miller C; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner E; Lyons RM; Paquette R; Raza A; Vaddi K; Erickson-Viitanen S; Sun W; Sandor V; Kantarjian HM Br J Haematol; 2013 May; 161(4):508-16. PubMed ID: 23480528 [TBL] [Abstract][Full Text] [Related]
37. Impact of ruxolitinib on myelofibrosis patients post allogeneic stem cell transplant-a pilot study. Pu JJ; Poulose J; Malysz J; Zhu J; Fanburg-Smith JC; Claxton DF; Bayerl MG Br J Haematol; 2019 Sep; 186(5):e130-e133. PubMed ID: 31115038 [No Abstract] [Full Text] [Related]
38. Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis. Arana Yi C; Tam CS; Verstovsek S Future Oncol; 2015; 11(5):719-33. PubMed ID: 25757677 [TBL] [Abstract][Full Text] [Related]
39. Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts. Al-Ali HK; Griesshammer M; Foltz L; Palumbo GA; Martino B; Palandri F; Liberati AM; le Coutre P; García-Hernández C; Zaritskey A; Tavares R; Gupta V; Raanani P; Giraldo P; Hänel M; Damiani D; Sacha T; Bouard C; Paley C; Tiwari R; Mannelli F; Vannucchi AM Br J Haematol; 2020 Jun; 189(5):888-903. PubMed ID: 32017044 [TBL] [Abstract][Full Text] [Related]
40. Clarifying the use of ruxolitinib in patients with myelofibrosis. Kremyanskaya M; Atallah EL; Hoffman R; Mascarenhas JO Oncology (Williston Park); 2013 Jul; 27(7):706-14. PubMed ID: 23977767 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]